1887
  1. Home
  2. A-Z Publications
  3. Qatar Medical Journal
  4. Volume 2021, Issue 2
  5. Article
Volume 2021, Issue 2
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Introduction: Central obesity appears to play a major role in the pathogenesis of metabolic disorders in polycystic ovary syndrome. Insulin resistance and carbohydrate disorders are associated with dysfunctional secretion of various adipokines by the adipose tissue.

Objectives: This study aimed to evaluate leptin, apelin, and visfatin against a background of carbohydrate metabolism parameters in patients diagnosed with polycystic ovary syndrome (PCOS).

Material and methods: The study group consisted of 40 patients with PCOS (mean age, 29 years) diagnosed in accordance with the American Society for Reproductive Medicine criteria from 2003. The control group consisted of 37 clinically healthy women (mean age, 26 years). All controls had regular menses and no clinical or biochemical signs of hyperandrogenism. Concentrations of leptin, apelin, visfatin, and insulin were measured by immunoenzymatic methods. Glucose concentrations were determined using spectrophotometry.

Results: Significantly higher concentrations of leptin, insulin, homeostatic model assessment for insulin resistance (HOMA-IR) index, and the immunoreactive insulin (IRI)/glucose index were found in the PCOS group than in the control group. Notably, the concentration of apelin was over five times lower in the PCOS group than in the control group. In patients with PCOS, a positive correlation was found between the concentrations of insulin and leptin and concentrations of leptin and IRI/glucose. Patients of the PCOS group with body mass index (BMI) ≥  25 had significantly higher values of leptin, insulin, HOMA-IR index, and IRI/glucose index than patients of the PCOS group with normal BMI. In the PCOS group, a positive correlation was found between BMI and leptin concentration (r = 0.7176;  < 0.0001) and carbohydrate metabolism, such as insulin (r = 0.5524; p = 0.0003), glucose (r = 0.3843; p = 0.0157), HOMA-IR (r = 0.5895; p < 0.0001), and IRI/glucose (r = 0.3872; p = 0.0163). These findings were not observed in the control group.

Conclusions: (1) Increased leptin concentration observed in women diagnosed with PCOS as well as positive correlations between leptin and HOMA-IR, and IRI/glucose and BMI may indicate a potential role of leptin in the reduction of tissue sensitivity to insulin. (2) Significantly lower apelin concentration in the PCOS group (>5 fold) than in the control group, associated with a concomitant increase in leptin, may also contribute to carbohydrate metabolism disorders occurring in the course of PCOS.

© 2021 Kolan′ska-Dams, Boinska, Socha, licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/qmj.2021.34
2021-08-31
2024-11-08
Loading full text...

Full text loading...

/deliver/fulltext/qmj/2021/2/qmj.2021.34.html?itemId=/content/journals/10.5339/qmj.2021.34&mimeType=html&fmt=ahah

References

  1. Milewicz A., Kudła M., Spaczyn′ski R.Z., De˛bski R, Me˛czekalski B, Wielgos′ M., et al. The polycystic ovary syndrome: a position statement from the Polish Society of Endocrinology, the Polish Society of Gynaecologists and Obstetricians, and the Polish Society of Gynaecological Endocrinology. Endokrynol Pol. 2018; 69:(4): 328–344.
     [Google Scholar]
  2. Walters K.A., Gilchrist R.B., Ledger W.L., Teede H.J., Handelsman D.J., Campbell R.E. New perspectives on the pathogenesis of PCOS: neuroendocrine origins. Trends Endocrinol Metab. 2018; 29:(12): 841–852.
     [Google Scholar]
  3. Li Y., Chen Ch., Ma Y., Xiao J., Luo G., Li Y., et al. Multi-system reproductive metabolic disorder: significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS). Life Sci. 2019; 228:: 167–175.
     [Google Scholar]
  4. Rosenfield R.L. The diagnosis of polycystic ovary syndrome in adolescents. Pediatrics. 2015; 136:(6): 1154–1165.
     [Google Scholar]
  5. Spritzer P.M., Motta A.B Adolescence and polycystic ovary syndrome: current concepts on diagnosis and treatment. Int J Clin Pract. 2015; 69:(11): 1236–1246.
     [Google Scholar]
  6. Mierzwicka A., Bolanowski M. New peptides players in metabolic disorders. Postepy Hig Med Dosw (online). 2016; 70:881–886.
     [Google Scholar]
  7. Mohaisen I.K. Serum levels of anti-Mullerian hormone, leptin, T3, T4 and TSH in women with polycystic ovary syndrome in Iraq. Indian J Public Health. 2019; 10:(7): 745–751.
     [Google Scholar]
  8. Murawska-Ciałowicz E. Adipose tissue – morphological and biochemical characteristic of different depot. Postepy Hig Med Dosw (online). 2017; 71:466–484.
     [Google Scholar]
  9. Borsuk A., Biernat W., Zie˛ba D. Multidirectional action of resistin in the organism. Postepy Hig Med Dosw (online). 2018; 72:327–337.
     [Google Scholar]
  10. Góralska M., Majewska-Szczepanik M., Szczepanik M. Immunological mechanisms involved in obesity and their role in metabolic syndrome. Postepy Hig Med Dosw (online). 2015; 69:1384–1404.
     [Google Scholar]
  11. Kuligowska-Jakubowska M., Dardzin′ska J., Rachon′ D. Disorders of carbohydrate metabolism in women with polycystic ovary syndrome (PCOS). Diabet. Klin. 2012; 1:(5): 185–195.
     [Google Scholar]
  12. O'Carroll AM., Lolait SJ., Harris LE., Pope GR. The apelin receptor APJ: journey from an orphan to a multifaceted regulator of homeostasis. J. Endocrinol. 2013; 219:(1): 13–35.
     [Google Scholar]
  13. Bertrand C., Valet P. Castan-Laurell I. Apelin and energy metabolism. Front Physiol. 2015; 6:115–124.
     [Google Scholar]
  14. Bongrani A., Mellouk N., Rame C., Cornuau M., Guérif F., Froment P., et al. Ovarian expression of Adipokines in polycystic ovary syndrome: A role for chemerin, omentin, and apelin in follicular growth arrest and ovulatory dysfunction? Int J Mol Sci. 2019; 20:(15): 3778–3806.
     [Google Scholar]
  15. Jiang T., Pan J., Su Y., Zhou H., Qiu M., Li X. : The relationship between polycystic ovary syndrome and vaspin, apelin and leptin. J Kunming Univ. 2016; 37:(10): 41–46.
     [Google Scholar]
  16. Zhu S., Sun F., Li W., Cao Y., Wang Ch., Wang Y., et al. Apelin stimulates glucose uptake through the PI3K/Akt pathway and improves insulin resistance in 3T3-L1 adipocytes. Mol Cell Biochem. 2011; 353:(1-2): 305–313.
     [Google Scholar]
  17. Cassar S., Teede H.J., Harrison C.L., Joham A.E., Moran L.J., Stepto NK. Biomarkers and insulin sensitivity in women with polycystic ovary syndrome: characteristics and predictive capacity. Clin Endocrinol (Oxf). 2015; 83:(1): 50–58.
     [Google Scholar]
  18. Oz.egowska K.E., Pawelczyk L.A.: The role of insulin and selected adipocytokines in patients with polycystic ovary syndrome (PCOS) – a literature review. Ginekol Pol. 2015; 86:(4): 300–304.
     [Google Scholar]
  19. Chakrabarti J. Serum leptin level in women with polycystic ovary syndrome: correlation with adiposity, insulin, and circulating testosterone. Ann Med Health Sci Res. 2013; 3:(2): 191–196.
     [Google Scholar]
  20. Murawska-Ciałowicz E. Adipose tissue - morphological and biochemical characteristic of different depot. Postepy HIg Med Dosc (online). 2017; 71:466–484.
     [Google Scholar]
  21. Pan W.W., Myers M.G. Leptin and the maintenance of elevated body weight. Nat Rev Neurosci. 2018; 19:(2): 95–105.
     [Google Scholar]
  22. Altinkaya S.Ö., Nergiz S., Küçük M., Yüksel H. Apelin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2014; 176:168–172.
     [Google Scholar]
  23. Teede H.J., Misso M.L, Costello M.F, Dokras A., Laven J., Moran L., et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum. Reprod. 2018; 33:(9): 1602–1618.
     [Google Scholar]
  24. Jahromi B.N., Dabaghmanesh M.H., Parsanezhad M.E., Fatehpoor F.: Association of leptin and insulin resistance in PCOS: A case-controlled study. Int J Reprod Biomed. 2017; 15:(7): 423–428.
     [Google Scholar]
  25. Kozakowski J., Zgliczyn′ski W. Body composition, glucose metabolism markers and serum androgens - association in women with polycystic ovary syndrome. Endokrynol Pol. 2013; 64:(2): 94–100.
     [Google Scholar]
  26. Nawrocka-Rutkowska J., Ciec′wiez S., Marciniak A., Brodowska A., Wiśniewska B., Kotlega D., et al. Insulin resistance assessment in patients with polycystic ovary syndrome using different diagnostic criteria-impact of metformin treatment. Ann Agric Environ Med. 2013; 20:(3): 528–532.
     [Google Scholar]
  27. Wang J., Wu D., Guo H., Li M. Hyperandrogenemia and insulin resistance: the chief culprit of polycystic ovary syndrome. Life Sci. 2019; 1:(236): 116940.
     [Google Scholar]
  28. Chang C.Y., Tsai Y.C., Lee C.H.,Chan T.F., Wang S.H., Su J.H. Lower serum apelin levels in women with polycystic ovary syndrome. Fertil Steril. 2011; 95:(8): 2520–2523.
     [Google Scholar]
  29. Kurowska P., Barbe A., Róz.ycka M., Chmielin′ska J., Dupont J., Rak A. Apelin in reproductive physiology and pathology of different species: a critical review. Int J Endocrinol. 2018; 2018: 1687–1698.
     [Google Scholar]
  30. Olszanecka-Glinianowicz M., Madej P., Nylec M., Owczarek A., Szanecki W., Skałba P., et al. Circulating apelin level in relation to nutritional status in polycystic ovary syndrome and its association with metabolic and hormonal disturbances. Clin Endocrinol. 2013; 79:238–242.
     [Google Scholar]
  31. Gul O.O., Cander S., Gul B., Açıkgoz E., Sarandol E., Ersoy C. Evaluation of insulin resistance and plasma levels for visfatin and resistin in obese and non-obese patients with polycystic ovary syndrome. Eur. Cytokine Netw. 2015; 26:(4): 73–78.
     [Google Scholar]
  32. Kim J.J., Choi Y.M., Hong M.A., Kim M.J., Chae S.J., Kim S.M., et al. Serum visfatin levels in non-obese women with polycystic ovary syndrome and matched controls. Obstet. Gynecol. Sci. 2018; 61:(2): 253–260.
     [Google Scholar]
  33. Zhang Y., Zhang H. Visfatin as a potential target in polycystic ovary syndrome. J Int Reprod Health/Fam Plan. 2016; 35:506–509.
     [Google Scholar]
  34. Olszanecka – Glinianowicz M., Madej P., Zdun D., Boz.entowicz – Wikarek M., Sikora J., Chudek J., et al. Are plasma levels of visfatin and retinol – binding protein 4 (RBP4) associated with body mass, metabolic and hormonal disturbances in women with polycystic ovary syndrome? Eur J Obstet Gynecol Reprod Biol. 2012;162:55–61.
     [Google Scholar]
  35. Rashad N.M.,Ayman Abd-Elrahmana M.N., El-Shal A.S., Amin A.I. Serum visfatin as predictive marker of cardiometabolic risk in women with polycystic ovary syndrome. Middle East Fertil Soc J. 2018; 23:(4): 335–341.
     [Google Scholar]
  36. Sun Y., Wu Z., Wei L., Liu C., Zhu S., Tang S. High-visfatin levels in women with polycystic ovary syndrome: evidence from a meta-analysis. Gynecol.Endocrinol. 2015; 31:(10): 808–814.
     [Google Scholar]
/content/journals/10.5339/qmj.2021.34
Loading
Adipokine levels and carbohydrate metabolism in patients diagnosed de novo with polycystic ovary syndrome
Qatar Medical Journal 2021, 34 (2021); https://doi.org/10.5339/qmj.2021.34
/content/journals/10.5339/qmj.2021.34
/content/journals/10.5339/qmj.2021.34
Loading

Data & Media loading...

  • Article Type: Research Article
Keyword(s): apelin, carbohydrate metabolism, leptin and polycystic ovary syndrome

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error